Omada Health Study Shows Improved Weight Loss With GLP-1 Care

SAN FRANCISCO, Calif. — October 20, 2026

Study Reports Greater Weight Loss and Body Composition Improvements

The study included 151 participants in Omada’s GLP-1 Care Track and 94 in a usual-care group, which could include medication alone or other lifestyle programs. More than one-quarter of the usual-care group reported using another lifestyle or wellness program during the study. After 12 weeks, Omada members lost an average of 6.0% of their starting body weight, compared with 3.3% among controls. Participants in the Omada group also experienced a greater reduction in body fat percentage, at 3.3 percentage points versus 1.6 percentage points, and a larger increase in muscle mass percentage, at 0.6 percentage points versus 0.2 percentage points. The study also reported greater improvements in well-being, physical functioning and confidence in the ability to lose weight among Omada members. Depression and anxiety symptoms declined by roughly 30%, with reductions significantly greater than those in the usual-care group. These results suggest that a structured virtual care program may support weight and body composition outcomes during GLP-1 treatment, although the study’s 12-week duration limits conclusions about long-term effects.

Virtual Care Program Combines Coaching, Exercise and Digital Tools

Omada’s GLP-1 Care Track provides support between physician visits through a coordinated care team and digital health resources. Members receive guidance from a dedicated health coach, access to GLP-1-specific peer support groups, digital tools for meal logging and behavior tracking, and AI-powered nutrition support. The program also offers access to an exercise specialist who develops a personalized exercise plan with input from a physical therapist. Participants monitored body composition at home using bioelectrical impedance scales. The program is designed to address concerns associated with rapid weight loss during GLP-1 therapy, including the potential loss of lean mass. Lean mass can account for 30% or more of weight lost, according to the announcement, and its reduction may affect resting metabolic rate, physical function and the risk of weight regain. Exercise and resistance training are recognized strategies for supporting body composition, while the study explored whether virtual lifestyle support could help improve these outcomes alongside medication. Omada Chief Medical Officer Thomas Tsang, MD, MPH, said the findings suggest that clinical support between doctor visits may help people achieve greater weight loss and better body composition while supporting muscle mass.

Omada Insights Lab Expands Real-World Weight Health Research

The study was completed through the Omada Insights Lab ANSWERS Initiative, which analyzes and shares real-world evidence from the company’s behavior-change weight health programs. Omada Clinical Research Scientist Lisa A. Stanton, PhD, presented the findings under the title “Improving GLP-1 Weight Loss Quality with a Virtual Lifestyle Companion Program” on October 20 during the Anti-Obesity Drugs & Emerging Therapies session at WOC 2026, held October 19–21. Omada Health combines human-led care teams, connected devices and AI-enabled technology to support people managing chronic conditions, including obesity, diabetes, hypertension, cholesterol and musculoskeletal conditions. The company reports having served more than two million members since launch across more than 2,000 employers, health plans, pharmacy benefit managers and health systems. The latest findings add to its research into how ongoing behavioral and clinical support can complement medication-based weight management. Further research would be needed to establish whether the observed differences persist over longer periods and translate into sustained clinical benefits.

Source::Omada Health,,press release